Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
Phase 2
Recruiting
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT06408168
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers
Not Applicable
Recruiting
- Conditions
- Cancer
- Interventions
- Behavioral: Meditation Program
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 400
- Registration Number
- NCT06409065
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Philadelphia Chromosome-Positive Acute Myeloid LeukemiaAdvanced Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06401603
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Phase 1
Recruiting
- Conditions
- Refractory Acute LeukemiaPediatric Relapsed
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06397027
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
Recruiting
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Diagnostic Test: Electroencephalogram (EEG)
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06389721
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Phase 1
Recruiting
- Conditions
- Lymphodepleting ChemotherapyMyeloid Malignancies
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06383572
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
Recruiting
- Conditions
- Mesonephric-like Adenocarcinoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2000
- Registration Number
- NCT06377527
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Comparison of Conspicuity of Masses and Architectural Distortions Between Wide- and Narrow-angle Digital Breast Tomosynthesis Systems
Recruiting
- Conditions
- Architectural DistortionsBreast Tomosynthesis
- Interventions
- Device: Digital Breast Tomosynthesis (DBT)
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT06373354
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy with Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
Phase 2
Recruiting
- Conditions
- OligoProgressive Metastatic Disease
- Interventions
- Procedure: Next-line Systemic TherapyProcedure: Local Consolidation Therapy
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT06367972
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Advanced Colorectal Cancer
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06369259
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath